Alteration of thioredoxin and glutaredoxin in the progression of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 39, Issue 4, 2014, Pages 787-797

  Arodin, Lisa ^a   Lamparter, Heidrun ^b   Karlsson, Håkan ^c   Nennesmo, Inger ^a   Björnstedt, Mikael ^a   Schröder, Johannes ^b   Fernandes, Aristi P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; glutaredoxin; mild cognitive impairment; thioredoxin

Indexed keywords

GLUTAREDOXIN; LACTATE DEHYDROGENASE; TAU PROTEIN; THIOREDOXIN; THIOREDOXIN 1;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; FEMALE; GERONTOPSYCHIATRY; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUMBAR PUNCTURE; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MITOCHONDRION; NERVE FIBER; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; VERY ELDERLY;

ALZHEIMER'S DISEASE; GLUTAREDOXIN; MILD COGNITIVE IMPAIRMENT; THIOREDOXIN;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; GLUTAREDOXINS; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; THIOREDOXINS;

EID: 84896841362     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131814     Document Type: Article

References (50)

1. Mancuso M, Orsucci D, LoGerfo A, Calsolaro V, Siciliano G (2010) Clinical features and pathogenesis of Alzheimer's disease: Involvement of mitochondria and mitochondrial DNA. Adv Exp Med Biol 685, 34-44.
2. Selkoe DJ (2011) Alzheimer's disease. Cold Spring Harb Perspect Biol 3, pii: a004457.
3. Zhu X, Lee HG, Casadesus G, Avila J, Drew K, Perry G, Smith MA (2005) Oxidative imbalance in Alzheimer's disease. Mol Neurobiol 31, 205-217.
4. Silva DF, Esteves AR, Oliveira CR, Cardoso SM(2011) Mitochondria: The common upstream driver of amyloid-beta and tau pathology in Alzheimer's disease. Curr Alzheimer Res 8, 563-572.
5. Romano AD, Serviddio G, de Matthaeis A, Bellanti F, Vendemiale G (2010) Oxidative stress and aging. J Nephrol 23(Suppl 15), S29-S36.
6. Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, Zhu X, Smith MA (2010) Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology 59, 290-294.
7. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, But-terfield DA, Markesbery WR (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64, 1152-1156.
8. Axelsen PH, Komatsu H, Murray IV (2011) Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease. Physiology (Bethesda) 26, 54-69.
9. Galimberti D, Scarpini E (2011) Inflammation and oxidative damage in Alzheimer's disease: Friend or foe? Front Biosci (Schol Ed) 3, 252-266.
10. Holmgren A (2000) Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid Redox Signal 2, 811-820.
11. Fernandes AP, Holmgren A (2004) Glutaredoxins: Glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. Antioxid Redox Signal 6, 63-74.
12. Gromer S, Urig S, Becker K (2004) The thioredoxin system-from science to clinic. Med Res Rev 24, 40-89.
13. Arnér ES, Holmgren A (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267, 6102-6109.
14. Lillig CH, Berndt C, Holmgren A (2008) Glutaredoxin systems. Biochim Biophys Acta 1780, 1304-1317.
15. Lillig CH, Berndt C (2013) Glutaredoxins in thiol/disulfide exchange. Antioxid Redox Signal 18, 1654-1665.
16. Stroher E, Millar AH (2012) The biological roles of glutare-doxins. Biochem J 446, 333-348.
17. Patenaude A, Murthy MR, Mirault ME (2005) Emerging roles of thioredoxin cycle enzymes in the central nervous system. Cell Mol Life Sci 62, 1063-1080.
18. Michelet L, Zaffagnini M, Massot V, Keryer E, Vanacker H, Miginiac-Maslow M, Issakidis-Bourguet E, Lemaire SD (2006) Thioredoxins, glutaredoxins, and glutathionylation: New crosstalks to explore. Photosyn Res 89, 225-245.
19. Nakamura T, Lipton SA (2011) Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenera-tive diseases. Cell Death Differ 18, 1478-1486.
20. Newman SF, Sultana R, Perluigi M, Coccia R, Cai J, Pierce WM, Klein JB, Turner DM, Butterfield DA (2007) An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J Neu-rosci Res 85, 1506-1514.
21. Calabrese V, Cornelius C, Stella AM, Calabrese EJ (2010) Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: Role of hormesis and vitagenes. Neurochem Res 35, 1880-1915.
22. Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella R, Kanski J, Pennisi G, Mancuso C, Stella AM, But-terfield DA (2006) Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal 8, 1975-1986.
23. Akterin S, Cowburn RF, Miranda-Vizuete A, Jimenez A, Bogdanovic N, Winblad B, Cedazo-Minguez A (2006) Involvement of glutaredoxin-1 and thioredoxin-1 in beta-amyloid toxicity and Alzheimer's disease. Cell Death Differ 13, 1454-1465.
24. Lovell MA, Xie C, Gabbita SP, Markesbery WR (2000) Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radic Biol Med 28, 418-427.
25. Ginsberg SD, Hemby SE, Lee VM, Eberwine JH, Trojanowski JQ (2000) Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol 48, 77-87.
26. Gil-Bea F, Akterin S, Persson T, Mateos L, Sande-bring A, Avila-Carino J, Gutierrez-Rodriguez A, Sundstrom E, Holmgren A, Winblad B, Cedazo-Minguez A (2012) Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer's disease brain. EMBO Mol Med 4, 1097-1111.
27. Schonknecht P, Pantel J, Kruse A, Schroder J (2005) Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young-old subjects. Am J Psychiatry 162, 2071-2077.
28. Levy R (1994) Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psy-chogeriatr 6, 63-68.
29. Pekkari K, Gurunath R, Arnér ES, Holmgren A (2000) Truncated thioredoxin is a mitogenic cytokine for resting human peripheral blood mononuclear cells and is present in human plasma. J Biol Chem 275, 37474-37480.
30. Lundberg M, Fernandes AP, Kumar S, Holmgren A (2004) Cellular and plasma levels of human glutaredoxin 1 and 2 detected by sensitive ELISA systems. Biochem Biophys Res Commun 319, 801-809.
31. Schonknecht P, Pantel J, Hunt A, Volkmann M, Buerger K, Hampel H, Schroder J (2003) Levels of total tau and tau protein phosphorylated atthreonine 181 in patients with incipient and manifest Alzheimer's disease. Neurosci Lett 339, 172-174.
32. Sultana R, Baglioni M, Cecchetti R, Cai J, Klein JB, Bastiani P, Ruggiero C, Mecocci P, Butterfield DA (2013) Lymphocyte mitochondria: Toward identification of peripheral biomarkers in the progression of Alzheimer disease. Free Radic Biol Med 65C, 595-606.
33. Sultana R, Butterfield DA (2009) Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J Bioenerg Biomembr 41, 441-446.
34. Yap LP, Garcia JV, Han D, Cadenas E (2009) The energy-redox axis in aging and age-related neurodegeneration. Adv Drug Deliv Rev 61, 1283-1298.
35. Venkateshappa C, Harish G, Mahadevan A, Srinivas Bharath MM, Shankar SK (2012) Elevated oxidative stress and decreased antioxidant function in the human hippocampus and frontal cortex with increasing age: Implications for neu-rodegeneration in Alzheimer's disease. Neurochem Res 37, 1601-1614.
36. Gil-Bea F, Akterin S, Persson T, Mateos L, Sande-bring A, Avila-Carino J, Gutierrez-Rodriguez A, Sundstrom E, Holmgren A, Winblad B, Cedazo-Minguez A (2012) Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer's disease brain. EMBO Mol Med 4, 1097-1111.
37. Hampel H, Broich K, Hoessler Y, Pantel J (2009) Biological markers for early detection and pharmacological treatment of Alzheimer's disease. Dialogues Clin Neurosci 11, 141-157.
38. Galluzzi S, Geroldi C, Amicucci G, Bocchio-Chiavetto L, Bonetti M, Bonvicini C, Cotelli M, Ghidoni R, Paghera B, Zanetti O, Frisoni GB (2013) Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. J Neurol 260, 640-650.
39. Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Ste-fanescu C (2010) Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 469, 6-10.
40. Johnson WM, Wilson-Delfosse AL, Mieyal JJ (2012) Dys-regulation of glutathione homeostasis in neurodegenerative diseases. Nutrients 4, 1399-1440.
41. Brautigam L, Schutte LD, Godoy JR, Prozorovski T, Gellert M, Hauptmann G, Holmgren A, Lillig CH, Berndt C (2011) Vertebrate-specific glutaredoxin is essential for brain development. Proc Natl Acad Sci USA 108, 20532-20537.
42. Bonda DJ, Wang X, Perry G, Smith MA, Zhu X (2010) Mito-chondrial dynamics in Alzheimer's disease: Opportunities for future treatment strategies. Drugs Aging 27, 181-192.
43. Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E (2008) Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci 9, 505-518.
44. Mecocci P, MacGarvey U, Beal MF (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36, 747-751.
45. Chen Y, Yu M, Jones DP, Greenamyre JT, Cai J (2006) Protection against oxidant-induced apoptosis by mitochondrial thioredoxin in SH-SY5Y neuroblastoma cells. Toxicol Appl Pharmacol 216, 256-262.
46. Enoksson M, Fernandes AP, Prast S, Lillig CH, Holmgren A, Orrenius S (2005) Overexpression of glutaredoxin 2 attenuates apoptosis by preventing cytochrome c release. Biochem Biophys Res Commun 327, 774-779.
47. Wu H, Xing K, Lou MF (2010) Glutaredoxin 2 prevents H(2)O(2)-induced cell apoptosis by protecting complex I activity in the mitochondria. Biochim Biophys Acta 1797, 1705-1715.
48. Saeed U, Durgadoss L, Valli RK, Joshi DC, Joshi PG, Ravin-dranath V (2008) Knockdown of cytosolic glutaredoxin 1 leads to loss of mitochondrial membrane potential: Implication in neurodegenerative diseases. PLoS One 3, e2459.
49. Coppede F, Migliore L (2010) Evidence linking genetics, environment, and epigenetics to impaired DNA repair in Alzheimer's disease. J Alzheimers Dis 20, 953-966.
50. Masutani H, Bai J, Kim YC, Yodoi J (2004) Thioredoxin as a neurotrophic cofactor and an important regulator of neuro-protection. Mol Neurobiol 29, 229-242.